Higher-dose vitamin D supplementation was associated with a 64% to 79% lower estimated risk of preeclampsia in high-risk pregnant women, according to a 2026 systematic review and network meta-analysis of eight randomized trials involving 4,078 women. However, Gram Research analysis notes the evidence is preliminary and based on limited studies, so these findings should inform future research rather than guide current clinical practice without doctor consultation.
Researchers analyzed eight clinical trials involving over 4,000 pregnant women to see if common supplements could prevent preeclampsia, a serious pregnancy condition. According to Gram Research analysis, higher doses of vitamin D showed the most promise, potentially reducing preeclampsia risk by up to 79% compared to placebo. However, the evidence is still limited and researchers emphasize these findings are early-stage. Statins and metformin showed mixed results. Scientists say we need bigger, better studies before doctors can confidently recommend these supplements to prevent this dangerous condition that affects both mothers and babies.
Key Statistics
A 2026 systematic review and network meta-analysis of eight randomized controlled trials involving 4,078 high-risk pregnant women found that vitamin D supplementation at 4,000 IU daily was associated with a 79% lower estimated risk of preeclampsia compared to placebo.
According to the same 2026 analysis, monthly vitamin D supplementation at 60,000 IU showed a 64% lower estimated risk of preeclampsia, though researchers emphasized these are associations from limited evidence, not proven clinical effectiveness.
In the 2026 network meta-analysis of preeclampsia prevention strategies, vitamin D ranked highest among three interventions studied (vitamin D, statins, and metformin), but researchers noted these rankings were exploratory given the sparse network of available trials.
The 2026 systematic review found that evidence for statins and metformin in preventing preeclampsia remained inconsistent and inconclusive, with wide confidence intervals indicating substantial uncertainty about their effectiveness.
The Quick Take
- What they studied: Whether three common medications or supplements (statins, metformin, and vitamin D) could prevent preeclampsia, a serious blood pressure condition that develops during pregnancy
- Who participated: 4,078 pregnant women at high risk for preeclampsia across eight different research studies conducted between 2020 and 2025
- Key finding: Higher-dose vitamin D (4,000 IU daily or 60,000 IU monthly) was linked to an estimated 64% to 79% lower risk of preeclampsia compared to placebo, though researchers stress this is an association, not proven cause-and-effect
- What it means for you: If you’re pregnant and at high risk for preeclampsia, vitamin D supplementation might be worth discussing with your doctor, but this research is still preliminary. Do not start any new supplements without medical guidance, as the evidence isn’t strong enough yet to make firm recommendations
The Research Details
Researchers conducted a systematic review and network meta-analysis, which means they searched five major medical databases for all randomized controlled trials testing statins, metformin, or vitamin D for preeclampsia prevention. They found eight qualifying studies published between 2020 and 2025. In these trials, pregnant women at high risk were randomly assigned to receive either one of these three treatments or a placebo (dummy pill). The researchers then combined the results using statistical methods to compare which treatment worked best.
A network meta-analysis is like creating a web of comparisons. Instead of just comparing vitamin D to placebo, researchers can also see how vitamin D compares to statins and metformin, even if no single study directly tested all three together. This approach helps identify which option might be most effective.
The main outcome they tracked was whether women developed preeclampsia. They also monitored secondary outcomes like gestational hypertension (high blood pressure during pregnancy), preterm birth, low birth weight, and whether babies needed intensive care after birth.
This research approach matters because preeclampsia is a serious and sometimes life-threatening condition affecting both mother and baby. Finding safe, affordable ways to prevent it could save lives. However, the researchers were careful to note that their network was sparse, meaning not many studies directly compared these treatments, so the findings should be viewed as hypothesis-generating rather than definitive guidance for clinical practice.
The certainty of evidence is rated as low. The researchers found only eight trials total, and these studies used different doses and populations, making direct comparison difficult. The confidence intervals around the vitamin D findings were wide, meaning there’s substantial uncertainty around the exact benefit. The researchers explicitly stated these findings should not be interpreted as proof of clinical effectiveness and are best used to design future studies, not to guide current medical practice.
What the Results Show
Higher-dose vitamin D showed the most promising results. Women taking 4,000 IU of vitamin D daily had an estimated 79% lower risk of preeclampsia compared to placebo (risk ratio 0.21). Women taking 60,000 IU monthly showed a 64% lower risk (risk ratio 0.36). These translate to absolute risk reductions of about 8% and 6%, respectively, based on the baseline risk observed in the studies.
However, the researchers emphasized that these are associations observed in the data, not proof that vitamin D causes the reduction. The confidence intervals were wide, indicating substantial uncertainty. For example, the true benefit could be anywhere from a 28% reduction to a 94% reduction for the daily dose, based on the statistical range provided.
Vitamin D also showed trends toward reducing preterm birth and low birth weight, though these findings were imprecise and not statistically significant. When researchers ranked all interventions by their probability of being most effective, vitamin D ranked highest, followed by statins, but these rankings were exploratory and should not be considered definitive.
Statins and metformin showed inconsistent evidence with very wide confidence intervals, meaning the data didn’t clearly support or refute their effectiveness. The researchers concluded that evidence for these two treatments remains limited and inconclusive.
Beyond preeclampsia prevention, the analysis examined several related pregnancy complications. Vitamin D supplementation showed trends toward lower rates of preterm birth (babies born before 37 weeks) and low birth weight, but these associations were weak and imprecise. No clear benefits emerged for gestational diabetes, respiratory distress syndrome in newborns, or neonatal intensive care unit admission rates. The limited number of studies reporting these outcomes meant researchers couldn’t draw firm conclusions about vitamin D’s effect on these secondary outcomes.
This systematic review builds on previous smaller studies suggesting vitamin D might help prevent preeclampsia. The network meta-analysis approach is novel because it allows comparison of three different interventions simultaneously. However, the researchers noted that the sparse network structure (few direct comparisons between treatments) limits how much we can learn from combining these studies. Previous individual trials had suggested promise for statins and metformin, but this comprehensive analysis found their evidence inconsistent and unreliable.
The study has several important limitations. First, only eight trials met inclusion criteria, which is a small number for drawing firm conclusions. Second, the trials used different vitamin D doses, making it hard to identify the optimal amount. Third, the studies were heterogeneous, meaning they differed in design, population characteristics, and measurement methods. Fourth, the network was sparse, meaning there weren’t many direct head-to-head comparisons between treatments. Fifth, the confidence intervals were wide, reflecting substantial uncertainty. Finally, the researchers noted that some evidence was indirect (inferred from comparisons rather than direct trials), which reduces confidence in the findings. The authors explicitly stated these limitations mean the findings should be considered hypothesis-generating rather than practice-changing.
The Bottom Line
Based on this research, vitamin D supplementation at higher doses (4,000 IU daily or 60,000 IU monthly) shows the most promise for reducing preeclampsia risk in high-risk pregnancies, but the evidence is still preliminary (low certainty). Pregnant women at high risk should discuss vitamin D supplementation with their obstetrician, who can assess individual circumstances and recommend appropriate doses. Statins and metformin cannot be recommended based on current evidence due to inconsistent findings. These recommendations carry low confidence and should not replace standard medical care.
This research is most relevant to pregnant women identified as high-risk for preeclampsia (those with previous preeclampsia, chronic hypertension, diabetes, or kidney disease). Healthcare providers caring for high-risk pregnant women should be aware of these preliminary findings. Women with normal-risk pregnancies should not assume these findings apply to them. Anyone considering vitamin D supplementation during pregnancy must consult their doctor first, as individual circumstances vary.
If vitamin D supplementation is started early in pregnancy, any protective effect would likely develop gradually throughout pregnancy. Preeclampsia typically develops in the third trimester, so supplementation would need to begin well before then. Researchers did not specify how long supplementation must continue or when benefits might appear, as this was not directly studied.
Frequently Asked Questions
Can vitamin D prevent preeclampsia during pregnancy?
Higher-dose vitamin D (4,000 IU daily or 60,000 IU monthly) showed associations with 64% to 79% lower preeclampsia risk in a 2026 analysis of eight trials. However, this is preliminary evidence, and researchers emphasize these are associations, not proven cause-and-effect. Discuss with your doctor before starting supplementation.
What dose of vitamin D is best for preventing preeclampsia?
The 2026 research found higher doses showed more promise: 4,000 IU daily or 60,000 IU monthly were associated with lower preeclampsia risk. However, the optimal dose remains uncertain. Your obstetrician should determine the appropriate dose based on your individual health status and needs.
Do statins or metformin help prevent preeclampsia?
The 2026 systematic review found inconsistent and limited evidence for both statins and metformin in preventing preeclampsia. Wide confidence intervals indicate substantial uncertainty. Current evidence does not support recommending these medications for preeclampsia prevention without further research.
Who should consider vitamin D supplementation during pregnancy?
Women at high risk for preeclampsia (those with previous preeclampsia, chronic hypertension, diabetes, or kidney disease) may benefit from discussing vitamin D supplementation with their obstetrician. The 2026 research focused on high-risk pregnancies, so findings may not apply to normal-risk pregnancies.
Is this research strong enough to change medical practice?
No. Researchers explicitly stated the 2026 findings are preliminary and hypothesis-generating, not sufficient to guide clinical practice. The evidence is based on only eight trials with limited direct comparisons. Larger, well-designed studies are needed before firm clinical recommendations can be made.
Want to Apply This Research?
- Track daily vitamin D supplementation dose and timing, plus weekly blood pressure readings (if monitoring at home), to identify any patterns or changes over time during pregnancy
- If recommended by your doctor, set a daily reminder to take vitamin D supplementation at the same time each day, and log it in the app to ensure consistency and track adherence
- Record prenatal visit dates and any preeclampsia screening results (blood pressure, protein in urine) to monitor for warning signs and maintain communication with your healthcare provider about supplementation effectiveness
This article summarizes research findings and should not replace professional medical advice. Preeclampsia is a serious medical condition requiring close monitoring by qualified healthcare providers. Do not start, stop, or change any medications or supplements during pregnancy without explicit guidance from your obstetrician or midwife. The findings presented are preliminary and based on limited evidence. Individual circumstances vary significantly, and what may be appropriate for one person may not be suitable for another. Always consult your healthcare provider before making any changes to your prenatal care plan.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.